Zimmer Biomet Holdings Inc (ZBH)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $19.53B
Last updated: Nov 17, 2026 at 11:06 AM ET
Zimmer Biomet Holdings Inc (ZBH) Stock Forecast
Analysts expect Zimmer Biomet Holdings (ZBH) to earn $8.55 per share in the fiscal year ending Dec 31, 2026, on revenue of $8.61B. Of 27 analysts, 8 rate the stock Buy or Strong Buy, 19 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 14 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 27 ratings average 2.63, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 30% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 7.4% |
| Buy | 6 | 22.2% |
| Hold | 19 | 70.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 27
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 5.0% and revenue estimates rise 3.4%.
- Fiscal year ending Dec 31, 2026
- $8.55
- EPS consensus, revenue $8.61B
- Fiscal year ending Dec 31, 2027
- $8.98
- EPS consensus, revenue $8.90B
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $8.55 | $8.30 to $8.60 | 27 | $8.61B | $8.60B to $8.63B | 25 |
| Dec 31, 2027 | $8.98 | $8.68 to $9.32 | 27 | $8.90B | $8.83B to $8.99B | 25 |
Quarterly Estimates
The EPS consensus falls from $2.51 for the quarter ending Dec 31, 2026 to $2.08 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.51 | $2.39 to $2.67 | 26 | $2.31B | $2.23B to $2.42B | 25 |
| Mar 31, 2027 | $2.08 | $2.00 to $2.18 | 18 | $2.15B | $2.12B to $2.17B | 13 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 26 upward and 21 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 14 | 3 |
| Fiscal year ending Dec 31, 2027 | 5 | 14 |
| Quarter ending Mar 31, 2027 | 7 | 4 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.2% from $8.53.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $8.55 | $8.54 | $8.53 | $8.53 | $8.53 | +0.1% |
| Fiscal year ending Dec 31, 2027 | $8.98 | $9.05 | $9.07 | $9.07 | $9.07 | -1.0% |
| Quarter ending Mar 31, 2027 | $2.08 | $2.11 | $2.12 | $2.12 | $2.12 | -1.8% |
Frequently Asked Questions About ZBH
What is the ZBH stock forecast?
Consensus analyst estimates put Zimmer Biomet Holdings's EPS at $8.55 for the fiscal year ending Dec 31, 2026, on revenue of $8.61B. The consensus rating from 27 analysts is Hold.
How do analysts rate ZBH stock?
Of 27 analysts covering Zimmer Biomet Holdings, 2 rate it Strong Buy, 6 Buy, 19 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from ZBH next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $8.55, with estimates from $8.30 to $8.60 from 27 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $8.98, with estimates from $8.68 to $9.32 from 27 analysts.
What revenue do analysts expect from Zimmer Biomet Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $8.61B, with estimates from $8.60B to $8.63B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $8.90B, with estimates from $8.83B to $8.99B.
How many analysts cover ZBH?
27 analysts rate Zimmer Biomet Holdings stock, and 27 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ZBH pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts